Crestor News
Most Popular Crestor Story
Can AstraZeneca continue to swear off major M&A?
Can AstraZeneca ($AZN) CEO David Brennan stick to his no-megadeals diet? Analysts are beginning to wonder, says Bloomberg, now that three of the company's promising drug candidates have stumbled. The Read more...
Latest Headlines
- January 20, 2012
- November 21, 2011
- November 15, 2011
- November 8, 2011
- October 5, 2011
- September 2, 2011
- August 31, 2011
- January 21, 2011
- December 16, 2010
- November 11, 2010
- October 28, 2010
- September 28, 2010
- September 14, 2010
- August 26, 2010
- July 29, 2010
- June 30, 2010
- June 29, 2010
- May 21, 2010
- April 27, 2010
- March 31, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
